Senzar Asset Management Lowers stake in Nevro Corp (NVRO)

Nevro Corp (NVRO) : Senzar Asset Management reduced its stake in Nevro Corp by 11.83% during the most recent quarter end. The investment management company now holds a total of 1,483,730 shares of Nevro Corp which is valued at $94 Million after selling 199,147 shares in Nevro Corp , the firm said in a disclosure report filed with the SEC on May 13, 2016.Nevro Corp makes up approximately 18.40% of Senzar Asset Management’s portfolio.

Other Hedge Funds, Including , Next Century Growth Investors boosted its stake in NVRO in the latest quarter, The investment management firm added 42,880 additional shares and now holds a total of 215,317 shares of Nevro Corp which is valued at $13.6 Million. Nevro Corp makes up approx 0.66% of Next Century Growth Investors’s portfolio.Nea Management Company reduced its stake in NVRO by selling 333,000 shares or 33.52% in the most recent quarter. The Hedge Fund company now holds 660,428 shares of NVRO which is valued at $41.9 Million. Nevro Corp makes up approx 2.76% of Nea Management Company’s portfolio.Blackrock Fund Advisors reduced its stake in NVRO by selling 7,012 shares or 1.55% in the most recent quarter. The Hedge Fund company now holds 445,266 shares of NVRO which is valued at $28.2 Million. Nevro Corp makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.Ifp Advisors Inc boosted its stake in NVRO in the latest quarter, The investment management firm added 455 additional shares and now holds a total of 3,215 shares of Nevro Corp which is valued at $200,809. Nevro Corp makes up approx 0.01% of Ifp Advisors Inc’s portfolio.

Nevro Corp closed down -0.65 points or -0.96% at $67.27 with 2,72,325 shares getting traded on Wednesday. Post opening the session at $68.07, the shares hit an intraday low of $67.09 and an intraday high of $68.67 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Nevro Corp reported $-0.33 EPS for the quarter, beating the analyst consensus estimate by $ 0.32 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.65. The company had revenue of $41.65 million for the quarter, compared to analysts expectations of $34.72 million. The company’s revenue was up 331.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.57 EPS.

Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.

Leave a Reply

Nevro Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nevro Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.